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Abstract 
 
The classification of diabetic nephropathy (DN) as a vascular complication of diabetes makes the 
possible involvement of histamine, an endogenous amine that is well known for its vasoactive 
properties, an interesting topic for study. The aim of the present review is to provide an extensive 
overview of the possible involvement of histamine in the onset and progression of DN. The evidence 
collected on the role of histamine in kidney function together with its well-known pleyotropic action 
suggest that this amine may act simultaneously on glomerular hyper-filtration, tubular inflammation, 
fibrosis development and tubular hypertrophy.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Abbreviations list  
 
AGEs = glycoxidation end-products; ALEs = advanced lipoxidation end-products; BMM = bone 
marrow derived macrophages; CNDP1 = carnosinase-1 gene; DN = diabetic nephropathy; EDHF = 
endothelium-derived hyperpolarizing factor; EDNO = endothelium-derived nitric oxide; GFR = 
glomerular filtration rate; HDC = histidine decarboxylase; HNEpCs = human nasal epithelial cells; 
HRs = histamine receptors; HUVECs = human umbilical vein endothelial cells; IL = interleukin; 
MAPK = mitogen activated protein kinase; MC = mast cells; NF-κB = nuclear factor-κB; NHE3 = 
Na+-H+ exchange 3;  NO = nitric oxide; PAS = periodic acid-Schiff; PBMCs = peripheral blood 
mononuclear cells; PKC = protein kinase C; RAAS = renin-angiotensin-aldosterone; SD = slit 
diaphragm; SGLT = sodium glucose co-transporter; SKCa = Ca2+-activated K+ channels; TF = tissue 
factor; TGF = tubulo-glomerular feedback ; TGF-β1 = transforming growth factor-β1; TNF-α = 
tumour necrosis factor; ZO-1 = Zonula Occludens 1 
 
Perspectives section: 
 
 Histamine is a vasoactive amine involved in inflammatory response and fibrosis processes in the 
kidneys. 
 DN can be considered a vicious self-potentiating circle between glomerular hyper-filtration, tubular 
inflammation, fibrosis development and tubular hypertrophy. 
 Histamine targeting may be suitable as an adjuvant treatment for DN furnishing an integrated 
vasculoprotection, chronic inflammation reduction and fibrosis prevention approach. 
 
 
 
 
 
 
  
Diabetic nephropathy (DN) affects about one third of diabetes mellitus patients and is associated with 
a substantially elevated mortality rate (1), which is due to an increase in all-cause mortality and a 
concomitant decline in renal function. The main pharmacological strategies for its treatment currently 
involve the blockade of the renin-angiotensin-aldosterone (RAAS) system. However, these 
approaches are suboptimal and their efficacy greatly depends on the early initiation of therapy. The 
search for new therapeutic strategies is therefore highly warranted, but still a challenge that requires 
a better understanding of DN pathogenesis. 
DN can be considered the result of the interactions between multiple metabolic and hemodynamic 
factors that activate common intracellular signalling pathways, such as protein kinase C (PKC), 
mitogen activated protein kinase (MAPK) and nuclear factor-κB (NF-κB), which, in turn, trigger the 
production of cytokines and growth factors, leading to renal disease (2). The RAAS system, 
endothelin and urotensin II are vasoactive hormones that have been extensively studied. Other 
mediators may be involved, although their relation to DN is still speculative. In particular, histamine, 
in keeping with its well-known vascular and pro-inflammatory effects, is an interesting target for 
exploration. Indeed, DN is considered a microvascular compliance of diabetes which establishes a 
vicious circle between glomerular hyper-filtration, tubular inflammation, hypertrophy and interstitial 
fibrosis development, with synergistic effects. The identification of mediators that can simultaneously 
affect these multiple events would translate into new pharmacological targets. Histamine was initially 
related to the vascular genesis of glomerular hyper-filtration. However, a more complex role for 
histamine can be hypothesised since the tubular hypothesis of DN pathogenesis was postulated. This 
review aims to elucidate histamine’s contribution to the vicious circle of DN. 
 
 
 
  
Histamine source in diabetic kidneys 
Markle R.A. et al. (1986) were the first to demonstrate that diabetic rats show an increase in whole 
kidney histamine content, of up to 45 %. Notably, they also used a pharmacological approach to 
provide the first evidence that this increase was due to the neo-synthesis of histamine from its 
precursor L-histidine by the histidine decarboxylase (HDC) enzyme. Indeed, the administration of  
the selective HDC inhibitor α-hydrazinohistidine (25 mg/kg/day ip for 2 weeks), inhibited this 
increase almost to control levels (3). These data are consistent with the increased systemic level of 
histamine reported in diabetic patients with peripheral vascular disease (4), suggesting that histamine 
may play a functional role in the development of diabetes and its microvascular complications. This 
hypothesis has been supported  by the more recent observation that the deletion of the histidine 
decarboxylase (HDC) enzyme, which synthesizes histamine from its precursor L-histidine and can 
therefore be considered a marker for histamine biosynthesis (5), prevents the development of 
autoimmune diabetes in NOD mice (6). However, these data draw attention to the question of whether 
the source of histamine in diabetic kidneys is systemic circulation or a local inducible histamine pool. 
The first hypothesis has actually been discarded after the observation of the presence of the HDC 
enzyme in the kidney specimens of both humans and mice. Indeed, the histamine concentration in the 
glomeruli was found to be much higher than the circulating concentration (10-6 M vs 10-8 M, 
respectively) (7). In particular, it was demonstrated, using an enzymatic assay on tissue homogenates, 
that diabetic rats show significantly higher HDC renal activity (+79 %) and no decreases in the 
activity of histaminase, which is one of the enzymes that catalyses histamine decomposition, in tissues 
(8). Consequently, an increase of up to 81% in histamine content in the kidneys of diabetic rats, as 
compared to controls, has also been demonstrated (9). Attempts to identify mast cells (MC) in the 
kidneys were pursued for a long time as mast cells are the main source of histamine in tissue. The 
MC number in the kidneys is typically very low (10), in non-diabetic conditions, unlike in other 
anatomical districts where MC can be constitutively found. However, their presence increases in a 
variety of human diseases (10), including DN. Increased numbers of MC that express type VIII 
  
collagen (11), as well as MC chymase and tryptase (12), have been observed in the renal biopsies of 
DN patients. Notably, several hyperglycaemia-related metabolic by-products (such as ROS and 
oxidized lipoproteins) trigger MC degranulation (13), which has been found to parallel the 
development of DN through the stages of the disease (12). The role of MC in DN involves the 
activation of the local RAAS systems, via the release, by MC, of chymase, a chymotrypsin-like serine 
protease potent inducer of angiotensin II (14). However, histamine that is released from MC may also 
contribute to RAAS system activation (15). In 1982, Schwertschlag U. and Hackenthal E. 
demonstrated that MC-derived histamine was able to stimulate the release of renin from rat kidneys 
by H2R activation (16). 
Despite HDC in MC is usually the major source of histamine and renal MCs are increased in DN 
together with the histamine levels, a non-MC HDC is considered to be the prevalent source of 
histamine. Indeed, three observations have to be considered: (i) renal histamine content in non-
diabetic conditions, in which MC number is very low, is already higher than plasmatic content (10-6 
M vs 10-8 M, respectively) (7); (ii) compelling evidence from both enzymatic assays (on homogenates 
of glomeruli and tubules from the medulla and cortex) and immunohistochemical analyses (on 
isolated cells and kidney specimens) revealed that HDC was localised mainly in the cortex, both in 
the glomerulus (7, 17) and tubules (18, 19); (iii) HDC expression on renal residential cells was found 
to be significantly up regulated in diabetic mice (19). Collectively, these data clearly demonstrate the 
existence of a local intra-renal inducible histamine pool. Interestingly, it has been shown that 
carnosine, which is a dietary essential amino acid whose plasmatic levels are low in chronic kidney 
disease patients (20), is an adjunctive reservoir for L-histidine. Carnosine, which is a dipeptide 
formed of β-alanine and L-histidine, has been found in several histamine-rich anatomical districts, 
including the kidneys, in an inverse correlation with histamine levels (21). Interestingly, 
polymorphism in the the gene encoding for carnosinase-1 (CNDP1), which is a circulating enzyme 
that degrades the dipeptide carnosine into β-alanine and L-histidine, has been associated with the risk 
of nephropathy in type 2 diabetic patients. However, carnosine treatment has been found to restrain 
  
glomerular apoptosis, to prevent podocyte loss and to reduce the expression of Bcl-2-associated X 
protein and cytochrome c (22), by inhibiting advanced glycoxidation end-product (AGEs) and 
advanced lipoxidation end-product (ALEs) formation (23), via an histamine independent pathway.  
The detrimental effect of histamine in diabetic kidneys can be mediated by all four of its receptors 
(HRs). Indeed, a complementary immunohistochemical and pharmacological approach has 
demonstrated that they are all expressed in the kidneys: H1R had the widest distribution as it was 
present in the glomeruli (podocyte and mesangial cells) and both the proximal and distal tubules; H2R 
shared the glomeruli (mesangial cells) and distal tubule localization with H1R; H3R seems to be 
restricted to the apical side of the principal cells of the collecting duct; H4R was found at the proximal 
tubules and at the loop of Henlé (7, 17, 24-27). Notably, the up-regulation of the histaminergic tone 
in the diabetic kidney is related to the over expression of at least two of the four histamine receptors 
(HRs), which is in accordance with the increased renal histamine levels; in particular, H3R (26) at the 
collecting duct, and H4R mainly at the proximal tubules and at the loop of Henlé (17, 25). The 
potential contribution of HR activation to the DN vicious circle will be explored below. 
Histamine and glomerular hyper-filtration 
Glomerular hyper-filtration stems from mechanical damage to the glomerulus that involves podocyte 
detachment and loss, extracellular matrix deposition and endothelial dysfunction. Histamine is 
thought to participate in at least two of these detrimental events: podocyte detachment and endothelial 
dysfunction. It is well accepted that glomerular hyper-filtration reflects generalised microvascular 
and macrovascular functional changes (28-30). Its well-known vasoactive properties (31), led 
scientists to think that the nascent or inducible histamine pool observed in experimental models of 
diabetes triggered micro-vessel alterations and large vessel hyper-permeability, thus contributing to 
both the diabetic microangiopathy and macroangiopathy (32), that are at the base of glomerular 
hyper-filtration. In the aortic endothelial and subjacent smooth muscle cells of diabetic rats, HDC 
activity increased by 250% and over 300%, respectively, over the 4-week period after diabetes 
induction. Parallel histaminase activity was reduced by 50% in the aortic endothelial cells and by 
  
30% in the subjacent smooth muscle cells and the intracellular histamine content increased to 138 % 
and 150%, respectively (33). The neo-synthesis of histamine at the aortic level was confirmed by the 
inhibitory effect of α-HH, which was also able to reduce the aortic albumin flux in diabetic rats by 
83% (34). It can therefore be stated that histamine is clearly a mediator of aortic macromolecule 
uptake in diabetes. Nevertheless, histamine levels in coronary circulation were found to increase 
during myocardial ischemia, irrespective of the incidence of risk factors, diabetes included (35). 
The increased histaminergic tone on the vascular level can trigger hyper-permeability in various 
microcirculatory beds. For instance, diabetic rats shown an increased blood-brain barrier permeability 
within 2 to 4 weeks after the onset of hyperglycaemia, and this effect was mediated by H1R (36-39).  
Youisf M.H. et al. (40) have demonstrated, in an ex-vivo perfused kidney model, that exogenous 
histamine-induced vasodilation in diabetic-rat-derived kidneys is mediated by both endothelium-
derived nitric oxide (EDNO) and the endothelium-derived hyperpolarizing factor (EDHF), which 
open the Ca2+-activated K+ channels (SKCa). SKCa have been found to have no impact on afferent 
arteriolar tone in normal kidneys (41). However, SKCa-mediated relaxation is reduced in the resistance 
arteries of diabetic rats (42-44). It is worth noting that the well-known anti-diabetic drug metformin 
has been found to restore SKCa-mediated vasodilatation, which  had been impaired by AGEs in rat 
mesenteric arteries (45). 
Histamine is known to act biphasically on vascular permeability: within seconds to minutes, it evokes 
a rapid transient increase in permeability that is caused by endothelial gaps (46-51), while within 
hours it causes prolonged vascular leakage by acting on the expression of the zonula occludens (ZO)-
1 protein (52). These events have been explored particularly at the ocular level in order to test the 
hypothesis that histamine may act as a mediator of diabetic retinopathy. Gardner T.W. (1995) 
demonstrated that histamine contributes to the retinal blood barrier permeability breakdown in 
diabetic retinopathy (53). H1R antagonism could therefore be a therapeutic strategy for diabetic 
retinopathy and the hypothesis of the use of a similar strategy for DN has also appeared (54). 
However, the Astemizole Retinopathy Trial, which aimed to evaluate the efficacy of the H1R 
  
antagonist in diabetic macular oedema, revealed no clinical effect (55), leading to the strategy being 
abandoned for the treatment of DN.  
In the kidney, histamine can affect the integrity of permeability barriers. Indeed, histamine has been 
reported to affect ZO-1 and P-cadherin expression in human immortalised podocytes (17). Both of 
these junctional proteins play pivotal roles in maintaining the cytoarchitecture of the slit diaphragm 
(SD), and disturbing them may contribute to podocyte detachment and loss. Notably, only 
chlorpheniramine, a selective anti-H1R, was effective in preserving SD integrity, including a potential 
positive effect on the prevention of podocyte loss and consequently on glomerular-filtration barrier 
integrity, while ranitidine (selective H2R antagonist) and JNJ7777120 (the H4R antagonist prototype) 
provided no effect (17). Histamine may therefore exert direct effects on glomerular hyper-filtration, 
through H1R, in addition to its well-known vascular activities. Notably, levocetirizine (0.5 mg/kg/day 
orally for 8 weeks) increased creatinine and urea clearance in a model of streptozotocin-induced 
diabetes in rats, and almost restored the glomerular filtration rate (GFR), while simultaneously 
reducing proteinuria and polyuria (56). Although a quantitative morphological analysis of the 
filtration barrier was not performed, the functional data, together with the classical histological by 
periodic acid-Schiff (PAS)- and Masson’s trichrome-staining, support the existence of a beneficial 
effect on glomerular filtration barrier integrity. These data are in keeping with the observation by 
Ichikawa and Brenner (1979) of a decrease in the ultrafiltration coefficient following H1R activation. 
Moreover, a drop in the GFR evoked by aortic clamping was observed after the infrarenal infusion 
of different H1R antagonists/inverse agonists (Banks 1984). However, in a model of anti-glomerular 
basement membrane induced glomerulonephritis both the H1R antagonist diphenhydramine and the 
H2R antagonist cimetidine prevented the GFR decrease (Wilson et al., 1981). GFR derives from the 
sum of the hydrostatic pressure in the glomerular capillaries, the hydrostatic pressure in the 
Bowman’s capsule or the proximal tubule, the colloid osmotic pressure of the glomerular capillaries 
and the colloid osmotic pressure of Bowman’s capsule (Persson et al., 2010). The early phase of DN 
is characterized by an increased GFR and renal plasma flow (Barnes et al., 1989). Histamine induced 
  
vasodilation (Yousif) could account at least in part to the early GRF increase observed in DN. Later 
on, with the disease progression the GFR declines in parallel with a further rise in albuminuria, 
consequently to an increase in the colloid osmotic pressure of the glomerular capillaries and 
hyperfiltration (Palatini et al., 2012), possibly through the disturbance of the tubulo-glomerular 
feedback (TGF) (Persson et al., 2010). Therefore, it is possible that the histamine receptors expressed 
on the tubules, proximal tubule in particular, could account for GFR decline in the later phase. 
Notably, apart the H1R, also H4R could be involved in GFR modulation, as its blockade by 
JNJ39758979 restored to control the drop in Creatinine Clearance, an approximate measure of the 
GFR, observed in after 15 weeks of diabetes in a mouse model of diabetes (PINI, 2018).  
Histamine and tubular inflammation 
Tubular inflammation is a hallmark of progressive renal disease (Tang and Lai, 2012). DN 
inflammation is sterile and chronic, triggered by intrinsic kidney cell injury (Zheng and Zheng, 2016), 
which can produce a number of chemokines promoting a proinflammatory microenvironment that 
amplifies renal injury (Lim and Tesch 2012). These events promote the kidney infiltration of 
monocytes and lymphocytes which further amplifies the inflammatory response, promotes cell injury 
and the development of fibrosis (Lim and Tesch 2012). 
The inflammatory properties of histamine were among the first properties described for the amine 
(57). Indeed, according to the triple response described by Lewis in 1924, the vascular changes that 
occur in acute inflammation are accompanied by the recruitment of neutrophils and mononuclears, 
which cross the endothelial junctions and penetrate the vessel wall. Leukocytes are thereafter 
recruited through chemotaxis. Two of the four HRs are implicated in these events: H1R promotes 
cellular migration (58), while H4R activation mediates eosinophil adhesion to the endothelium, and 
chemotaxis (59), up-regulating the cell-surface proteins CD11b/CD18 (Mac-1) and CD54 (ICAM-1) 
on human eosinophils (60). Following H4R activation, the rearrangement of the actin cytoskeleton of 
eosinophils facilitates cell migration into the inflammation sites (61). Notably, Dai D.F. et al. (62) 
  
have demonstrated that interstitial eosinophil aggregation is more common in the renal biopsies of 
DN patients than in other types of glomerulopathy, such as IgA nephropathy, membranous 
nephropathy and membranoproliferative glomerulonephritis. Moreover, the severity of interstitial 
fibrosis and tubular atrophy was the only predictor factor for interstitial eosinophil aggregation in 
DN. It is reasonable to conclude that eosinophil aggregation is a consequence of inflammatory 
response and that it perpetuates tubulointerstitial injury. Notably, the preventive chronic 
administration of the H4R antagonist JNJ39758979 (Ki = 12.5 ± 2.6 nM) led to a significant reduction 
in the number of leukocytes, compared to untreated diabetic animals, 15 weeks after diabetes onset 
in a model of streptozotocin-induced DN in DBA2/J mice (19).  
The chemotactic effects of histamine not only involve eosinophils, but also neutrophils: they evoke 
lysosomal enzyme release (63), and thus enhance the inflammatory response to direct tissue damage. 
Histamine is also involved in T cell proliferation and lymphokine release, the induction of cytotoxic 
T cells and the promotion of their cytolytic activity, as well as B cell differentiation into effector cells 
(64). All these infiltrating cells contribute, together with macrophages, dendritic cells, and renal 
tubular cells to inflammation in DN (Zheng and Zheng, 2016). 
Beyond inflammatory cell recruitment, histamine is also known to exert other inflammatory 
properties in several cellular systems. For instance, histamine activates the NF-κB pathway by 
inducing the expression of NF-κB p65 and p-IκBα in human nasal epithelial cells (HNEpCs) (65). 
The H1R antagonist cetirizine has been demonstrated to not only inhibit the recruitment and activation 
of inflammatory cells, but to also suppress the production of reactive oxygen radicals and lipid 
mediators (66-69). It is therefore possible to speculate that similar effects are evoked by histamine in 
renal cells. 
More interestingly, histamine, acting both as a paracrine and  autocrine stimulus, has been observed 
to increase the mRNA levels of interleukin (IL)-6 (65), a cytokine involved in several renal diseases 
including DN (70, 71). In particular, IL-6 overexpression in diabetic kidneys has been correlated with 
  
kidney hypertrophy, albumin excretion, mesangial expansion and glomerular basement membrane 
thickening (Lim and Tesch, 2012).  
Another factor that has been extensively linked to DN is IL-18 (72), which serum and urinary levels 
have been previously correlated with albuminuria [50, 91]. The major source of this pro-
inflammatory cytokine are the tubular epithelial cells, but it is produces by infiltrating 
monocyte-macrophages and T cells [89, 90]. The induction of IL-18 secretion from peripheral 
blood mononuclear cells (PBMCs) (73) may be an additional contribution to the inflammatory milieu 
of DN by histamine. However, a more recent study has demonstrated the existence of functional 
antagonism between IL-18 and histamine, which occurs via H2R stimulation, in monocyte ICAM-1 
expression (74). 
On the other hand, the effect of histamine on tumour necrosis factor (TNF)-α, another relevant pro-
inflammatory cytokine that is associated/involved with DN and interstitial tubular nephritis (75), is 
contradictory. TNF-α has been implicated haemodynamic changes affecting the GFR [45–48] 
and the endothelial permeability [49] and its urinary excretion has been correlated with DN 
progression [52]. TNF-α is produced not only by monocytes, macrophages, and T cells, but also 
by all the resident renal cells (Lim and Tesch, 2012). Moreover, TNF-α is stored and released by 
MC and can be released (76) together with histamine, which in turn can stimulate the release of TNF-
α in an autocrine manner (77). However, histamine has been reported to antagonise TNF-α by 
shedding its receptor, TNFR1, via H1R activation in human umbilical vein endothelial cells 
(HUVECs) (78) and to suppress TNF-α synthesis via H2R in PBMC and monocytes (79). 
Finally, histamine is also able to activate the Tissue Factor (TF) pathway. It has been reported that 
endothelial TF expression and activity is induced by histamine (80), via H1R activation (81). TF 
expression is induced in vascular inflammation and involved in DN development (72), with its 
increasing associated with DN severity (WANG et al., 2010).  
  
Histamine and tubular fibrosis 
The inflammatory properties of histamine and its role in promoting and sustaining inflammatory cell 
infiltration are linked to fibrosis development, which suggests that histamine may be a target for the 
management of kidney fibrosis. Glomerular and tubulointerstitial infiltration by inflammatory cells, 
including neutrophils, macrophages and lymphocytes, which release pro-fibrotic cytokines (82), 
occurs from the early stage of DN. Such cellular infiltrates have been reported in both animal 
experimental models and human renal biopsies (83). Of the various inflammatory cells involved, a 
prominent role can be attributed to macrophages, whose accumulation has been related to the severity 
of DN (84).  
The differentiation of monocytes into macrophages has been associated with an imbalance in the 
native HRs on these cells. H1R is up-regulated during differentiation, thus increasing the 
histaminergic response, while H2R is down-regulated (85). The role of histamine in macrophage 
activation is further confirmed by in vitro data. H4R induces chemotaxis and phagocytosis in both 
human (RAW 264.7 cell line) and murine (bone marrow derived macrophages - BMM) monocytes 
(86). Finally, macrophages and lymphocytes have also been found to be an alternative source of 
histamine, with a content of ca. 0.05 pg histamine/cell, in a histamine-specific radioimmunoassay. 
Both the ionophore A23187 and the complement component 5a caused histamine release, of up to 
50% and 40%, respectively, from monocytes (87).  
Once again histamine is seen to induce and perpetuate the pathological events that underlie renal 
failure in DN, exerting both autocrine and paracrine effects on a range of inflammatory cells. 
Macrophages are also a major source of transforming growth factor-β1 (TGF-β1), which is the master 
regulator of fibrosis and a potent chemoattractant for macrophages/monocytes. In DN, TGF-β1 can 
be considered one of the principal mediators of parenchymal/stromal alterations, which  finally lead 
to tissue architecture disruption (88). TGF-β1 up-regulation causes the imbalance in extracellular 
matrix turn-over, promoting the excessive deposition of collagen fibres and inhibiting their 
  
degradation at the same time. TGF-β1 also causes the trans-differentiation of parenchymal into 
stromal cells. For example, it brings about the transformation of tubule epithelial cells into 
myofibroblasts (89, 90). This process is responsible for interstitial renal fibrosis. TGF-β1 over-
expression, together with the consequent extracellular matrix accumulation and parenchymal cell 
trans-differentiation, is closely associated with renal failure (91). TGF-β1 is therefore an attractive 
target when attempting to counteract fibrotic processes. The only current strategy that directly targets 
TGF-β1 is based on the use of monoclonal antibodies, such as fresolimumab, for the treatment of 
pulmonary fibrosis (92). It has been tested in a phase 1 study for primary focal segmental 
glomerulosclerosis (93). However, recent data suggest that antihistamine anti-H4R compounds can 
be used to regulate TGF-β1 release and effects. Indeed, in vivo studies carried out on a model of 
bleomycin-induced lung fibrosis clearly demonstrate that H4R antagonism counteracts fibrosis 
establishment by acting on TGF-ß production (94, 95). TGF-β, in turn, modulates the fibrotic process 
by impacting upon downstream signalling. Notably, the down-regulation of TGF-β by JNJ7777120 
(the H4R antagonist prototype) has been sustained by a reduction in Smad 3 phosphorylation and, 
consequently, Smad3/Smad4 complex formation (94). The Smad family is one of the most-commonly 
studied pathways and is closely involved with TGF-β1. Focusing on the renal fibrotic process, the 
presence of Smad 3 and Smad 4 has been evaluated as being pathogenic while that of Smad 2 and 
Smad 7 has been related to renoprotective effects (96-99). The decreased level of Smad 7 expression 
causes persistent inflammation and, as result, leads to renal fibrosis via TGF-β and Smad 3. It is 
therefore plausible that the anti-fibrotic effect exerted by JNJ39758979 in a model of murine DN 
(19), is related, at least partially, to the modulation of TGF-β/Smad signalling in the kidneys. 
Nevertheless, H1R can also modulate the fibrotic response. Indeed, levocetirizine-treated diabetic rats 
have shown a reduction in renal TGF-β1 (56). Whether this is a direct consequence of H1R 
antagonism, or rather an indirect event is still to be established. However, the anti-inflammatory 
effect, evaluated in terms of the restoration of TNF-α levels and nitric oxide (NO) bioavailability  
(56), may be a possible mechanistic interpretation of the anti-fibrotic result. Moreover, the presence 
  
of the H1R on kidney fibroblasts, whose activation promotes proliferation, TGF-β synthesis and 
collagen production (Silver - 2013), further support the involvement of this receptor in fibrosis 
development.  
Actually, no other study apart the one from Pini et al. (2018) and Anbar et al. (2016) evaluated the 
effect of histamine blockade on renal fibrosis during DN, therefore just speculation are possible so 
far. However, the measurements of TGF-β1 renal level in diabetic rats treated with levocetirizine and 
the evaluation by Picrosirius red staining of collagen fibre deposition after JNJ39758979 (Anbar) 
treatment of diabetic mice (Pini) support the hypothesis that at least H1R and H4R are both involved, 
directly or indirectly (through the reduction of pro-inflammatory infiltrating cells), in renal fibrosis 
development.  
Histamine and tubular reabsorption 
Recently, proximal tubule as initiator, driver or contributor in the pathogenesis of DN become an 
intriguing hypothesis. Impaired tubular uptake and increased glomerular leakage are both potentially 
responsible for microalbuminuria early stage of DN (Zeni et al., 2017). Indeed, the existence of the 
TGF can explain a reduction in GFR during inhibition of proxiaml tubular reabsorption: the increased 
electrolyte load to the macula densa due to a reduction in reabsorption led to afferent arteriolar 
vasoconstriction and consequqntly to a GFR correction (Persson and Wright, 1982). Sodium and 
chloride appear to be the preferential elctrolyte regulating the TGF. This tubulo-centric hypothesis 
could be considered the basis for the development of the newest antidiabetic class, the sodium glucose 
co-transporter (SGLT)-2 inhibitors. Interestingly, their nephro-protective effects can be due to a 
functional link between SGLT2 and the Na+-H+ exchange 3 (NHE)3, an important determinant of 
Na+ tubular reabsorption, according to which when SGLT2 is inhibited also NHE3 is inhibited (Zeni 
et al., 2017). 
Tubular reabsoprtion impairment could also contribute to albuminuria onset in DN (Dickson et al., 
2014). Despite the canonical idea of an increase in creatinine and urinary albumin excretion due to 
  
glomerular hypertension and hyperfiltration in the early phase of DN (Brenner et al., 1996), more 
recent evidence are in favour of an unchanged glomerular albumin filtration, but a decrease in tubular 
albumin reabsorption (Tojo et al., 2001; Russo et al., 2009). Major contributor to albumin dynamics 
associated with the hyperfiltration status of DN is the megalin/cubilin complex (Amsellem et al., 
2010). Interestingly, in two models of insulin-deficient diabetes in drug-inducible megalin knockout 
mice, both albumin filtration and reabsorption were increased (Mori et al., 2017).  
Overall these evidence hilihgts the importance of tubular reabsorptive processes in DN onset and 
progression. 
The role of histamine in tubular reabsorption has been less investigated than the other fields. 
Therefore, only speculation can be made, and most of them are based on a parallelism with other 
epithelial tissues. The only reabsorption mechanisms that have seen some partial investigation are the 
megalin and NHE3 pathways in the proximal tubule. Hyperglycaemia is known to induce a reduction 
in megalin expression and a parallel increase in NHE3 expression and activity (100). JNJ39758979 
treatment preserved the expression and apical membrane localisation of megalin as well as the 
expression level of NHE3 in a mouse model of DN. These events were paralleled by a restoration of 
the albumin-to-creatinine ratio and creatinine clearance and by preserved glomerular integrity (19). 
In accordance with the tubular hypothesis of DN (101), it is therefore possible to speculate that 
JNJ39758979's beneficial effect on renal function is a consequence of its beneficial effect on the 
tubular reabsorption machinery. However, the question of whether this is a direct H4R-blockade effect 
is still far from being answered. Indeed, we can only speculate whether histamine has a direct 
detrimental effect on the megalin and NHE3 pathways in terms of parallelism between the angiotensin 
AT-1 receptor and H4R, which are both Gi-coupled receptors. Similarly to JNJ39758979, losartan 
has also been reported to reduce NHE3 expression (102). However, the possibility of it being an 
indirect effect exerted by JNJ39758979 and secondary to RAAS modulation could not be ruled out. 
Moreover, even if JNJ39758979 is a selective H4R antagonist, a class-effect has to be demonstrated 
to affirm whether H4R-dependent downstream signals are responsible for the detrimental effect of 
  
histamine on the tubular reabsortive machinery. If we consider the other reabsorption pathways in the 
tubules, the correlation with histamine becomes even more speculative. An explicative example can 
be found in the potential contribution of histamine to water-balance in the kidneys, which is usually 
dysregulated in DN, leading to the onset of polyuria. Several water channels, named aquaporins 
(AQPs), are involved in water transport across the epithelia. At least 9 types, including AQP-1-8 and 
AQP-11 that are present at distinct sites and have specific functions, have been identified in the 
kidneys (103). In particular, AQP-2 and AQP-5 urinary excretion has been observed to increase 
significantly in DN patients and a positive correlation between AQP level in urine and the histological 
class of DN has been established. Indeed, AQP-2 and AQP-5 were appointed as novel non-invasive 
biomarkers to help in classifying the clinical stage of DN (103). Interestingly, an in vitro study on 
human nasal epithelial cells has revealed that histamine down-regulates AQP5 expression via NF-κB 
activation and the consequent reduction in the phosphorylation of cyclic adenosine monophosphate 
(cAMP) response element-binding protein (CREB) (104, 105). These effects were mediated by H1R, 
as demonstrated by the ability of chlorpheniramine to reverse histamine’s inhibitory effect (105). 
Moreover, H1R activation induced AQP-5 translocation to the plasma membrane in human 
submandibular gland cells, which, at least partly, explains the xerostomia that is induced by the classic 
antihistaminic anti-H1R drugs (106). Histamine has also been found to induce gastric AQP-4 
rearrangement and down-regulation (107). It is therefore possible that histamine may also modulate 
AQP expression, via H1R and/or other HRs, in other epithelial cells, such as renal epithelial cells, 
according to their differential distribution. A deeper investigation of this issue would contribute to 
better understanding the mechanism that underlies the anti-polyuric effect that is exerted by both 
levocetirizine (56), and JNJ39758979 (19). 
Conclusion 
Spare evidence has been provided as to histamine’s possible role in DN in past decades (108). 
Although its vasoactive and inflammatory properties may make histamine’s role in DN progression 
plausible, this idea has not been thoroughly investigated. Initial data did not clearly establish its direct 
  
contribution to renal pathophysiology, meaning that this amine has been relegated to the background 
of diabetic disease, and its role in DN development has not been recognised. Only two studies have 
investigated the effect of an antihistaminergic approach on DN, both in recent years. These studies 
suggest that histamine is involved in renal injury and both the selective histamine antagonism, at H1R 
by levocetirizine (56), and at H4R by JNJ39758979 (19), were able to prevent/reduce renal damage. 
However, defining whether these beneficial effects are due to the selective contribution of the HRs 
in the kidney is still quite the challenge. While improved glycaemic status in diabetic rats was reported 
with levocetirizine (56), the same positive effect was not observed with JNJ39758979 (19). It can 
therefore be stated that at least H4R seems to have a selective role in renal function. However, H1R 
has been demonstrated to also have specific effects on podocyte junctional integrity, at least in vitro, 
which may contribute to renal protection. Nevertheless, the fact that indirect effects are induced by 
limiting the anti-inflammatory response can be recognised for both H1R and H4R antagonism. This 
evidence supports the idea that histamine, due to its pleiotropic actions, may simultaneously and 
differentially act on all the components of the vicious circle; glomerular hyper-filtration, tubular 
inflammation, tubular hypertrophy and fibrosis establishment. Indeed, as described in Figure 1, H1R 
antagonism potentially maintains glomerular integrity (17, 56), while H4R antagonism protects 
against reabsorptive dysfunction, counteracting the unbalance of megalin/NHE3 expression at the 
proximal tubule (19). Both strategies are simultaneously effective in preventing the pro-inflammatory 
and pro-fibrotic cascade, which leads to the loss of kidney function (19, 56). The roles of H2R and 
H3R are still far from being clear. However, their localisation along the nephron means that they may 
subserve water homeostasis, while H2R probably contributes to glomerular mechanical damage. 
Targeting histamine might therefore be a novel strategy for the treatment of DN with an integrated 
approach of vasculoprotection, chronic inflammation reduction and fibrosis prevention. However, 
these suggestions merit better elucidation, including first clinical evaluations, before final conclusions 
can be reached. 
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Figure caption 
Figure 1. Histamine's role in the development and progression DN. 
 
Figure 2. Histamine receptors in the pathophysiology of DN. 
DN is accompanied by an increase in renal histamine content, which can trigger and/or sustain the 
vicious circle established by glomerular mechanical damage, tubular inflammation, fibrosis 
development and tubular reabsorptive dysfunction. The strongest evidence has been found for H4R, 
which is localised on the proximal tubule (a) and on the loop of Henlé (d), and is involved in tubular 
inflammation, fibrosis and reabsorptive dysfunction. Besides promoting tubular inflammation, H1R 
may be involved in glomerular injury, which is consistent with its localisation in the glomerulus, but 
also in the tubule in both the proximal (a) and distal (b) tract. A similar effect for H2R, which is again 
present in the glomerulus and distal tubule (b), can be just hypothesised. A possible role for H3R in 
reabsorptive dysfunction can be hypothesised on the basis of its localisation in the collecting duct (c). 
